Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
An Observational Study to Evaluate the Clinical and Biologic Features and Outcome of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated With Venetoclax-based Regimens Outside Clinical Trials in Italy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Paola Fazi
- Phone Number: 0670390528
- Email: p.fazi@gimema.it
Study Contact Backup
- Name: Enrico Crea
- Phone Number: 0670390514
- Email: e.crea@gimema.it
Study Locations
-
-
-
Alessandria, Italy
- Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia
-
Bari, Italy
- Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
-
Cagliari, Italy
- Ao Brotzu, Presidio Ospedaliero A. Businco - Cagliari - Sc Ematologia E Ctmo
-
Catania, Italy
- CTC U.O di Ematologia con Trapianto di Midollo Osseo - Catania
-
Catanzaro, Italy
- Ao Di Catanzaro "Pugliese-Ciaccio", Presidio Ospedaliero "Ciaccio - de Lellis" - Ematologia
-
Cosenza, Italy
- Ao Di Cosenza, Presidio Ospedaliero Annunziata - Uoc Ematologia
-
Florence, Italy
- AOU Careggi - Firenze - SOD Ematologia
-
Messina, Italy
- Ao Ospedali Riuniti "Papardo Piemonte" - Po Papardo - Messina - Sc Ematologia
-
Milan, Italy
- Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia
-
Milan, Italy
- Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora
-
Milan, Italy
- Irccs Ospedale S. Raffaele - Milano - Unità Neoplasie Linfocitarie B
-
Modena, Italy
- Aou Di Modena - Sc Ematologia
-
Novara, Italy
- Aou Maggiore Della Carita' Di Novara - Scdu Ematologia
-
Palermo, Italy
- Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo
-
Perugia, Italy
- AO di Perugia, Ospedale S. Maria della Misericordia - Ematologia E Trapianto Midollo Osseo
-
Pisa, Italy
- Aou Pisana - Uo Ematologia Universitaria
-
Ravenna, Italy
- Ausl Della Romagna, Ospedale "Santa Maria Delle Croci" - Ravenna - Ematologia
-
Reggio Calabria, Italy
- Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Po E. Morelli - Reggio Calabria - Uoc Ematologia
-
Reggio Emilia, Italy
- Ausl Di Reggio Emilia - Arcispedale Santa Maria Nuova, Irccs - Sc Ematologia
-
Roma, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Roma - Area Ematologica
-
Roma, Italy
- Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
-
Terni, Italy
- Ao S. Maria - Terni - Sc Onco Ematologia
-
Torino, Italy
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia - Università Degli Studi Di Torino
-
Torino, Italy
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2
-
Varese, Italy
- Asst Dei Sette Laghi, Ospedale Di Circolo E Fondazione Macchi - Uoc Ematologia
-
Verona, Italy
- Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
-
-
Ferrara
-
Cona, Ferrara, Italy
- Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
- Patients with R/R CLL fulfilling the eligibility criteria required by the Venetoclax Named Patient Program who have received at least 1 dose of venetoclax.
- Patients with CLL who have received at least 1 dose of venetoclax or are scheduled to start treatment with venetoclax according to the Post-marketing Use before June 30th, 2025.
- Signed informed consent document (if feasible) according to ICH/EU/GCP and national local laws indicating that the patients understand the purpose of the study and they agree to give complete access to their medical records.
Exclusion Criteria:
None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
cohort group
Patients who have received at least one dose of venetoclax
|
Patients treated with venetoclax-based regimens outside clinical trials in Italy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimation of the PFS in relapsed/refractory (R/R) patients with CLL treated with venetoclax-based regimens according to the local label outside clinical trials in Italy.
Time Frame: 15 months
|
Estimation of the PFS at 15 months from the start of venetoclax treatment in patients with R/R CLL who started treatment with venetoclax-based regimens according to the local label from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021
|
15 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Leukemia, Lymphoid
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Agents
- venetoclax
Other Study ID Numbers
Other Study ID Numbers
- CLL1920
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.